Literature DB >> 18504168

Modern therapy of rectal carcinoma.

H Matthaei1, E Bölke, M Schmelzle, W Budach, K Orth, R Engers, M Cohnen, C Matuschek, S Gripp, W T Knoefel, Matthias Peiper.   

Abstract

Throughout the past decade the treatment of rectal carcinoma has improved remarkably. Today, individualized multimodality treatment allows local and distant tumor freedom with preservation of anorectal and genitourinary function in a majority of patients. Radiotherapy is elementary in reducing the risk of local recurrence whereas chemotherapy including promising novel agents prevents or eliminates distant metastases. However, surgery revolutionized by TME (total mesorectal excision) remains the only curative treatment for rectal carcinoma. In this study the authors review the developments as well as the current status of modern treatment for rectal carcinoma.

Entities:  

Mesh:

Year:  2008        PMID: 18504168

Source DB:  PubMed          Journal:  Eur J Med Res        ISSN: 0949-2321            Impact factor:   2.175


  4 in total

Review 1.  Patterns of colorectal cancer care in Europe, Australia, and New Zealand.

Authors:  Neetu Chawla; Eboneé N Butler; Jennifer Lund; Joan L Warren; Linda C Harlan; K Robin Yabroff
Journal:  J Natl Cancer Inst Monogr       Date:  2013

2.  Methylated APC and GSTP1 genes in serum DNA correlate with the presence of circulating blood tumor cells and are associated with a more aggressive and advanced breast cancer disease.

Authors:  C Matuschek; Edwin Bölke; G Lammering; P A Gerber; M Peiper; W Budach; H Taskin; H B Prisack; G Schieren; K Orth; H Bojar
Journal:  Eur J Med Res       Date:  2010       Impact factor: 2.175

3.  Gene expression of circulating tumour cells and its correlation with tumour stage in breast cancer patients.

Authors:  E Bölke; K Orth; P A Gerber; G Lammering; R Mota; M Peiper; C Matuschek; W Budach; E Rusnak; S Shaikh; B Dogan; H B Prisack; H Bojar
Journal:  Eur J Med Res       Date:  2009-08-12       Impact factor: 2.175

4.  Gene expression of circulating tumour cells in breast cancer patients.

Authors:  E Bölke; K Orth; P A Gerber; G Lammering; R Mota; M Peiper; C Matuschek; W Budach; E Rusnak; S Shaikh; B Dogan; H B Prisack; Hans Bojar
Journal:  Eur J Med Res       Date:  2009-09-28       Impact factor: 2.175

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.